Department of Mechanical and Aerospace Engineering

Dr. Umut Gurkan is the lead PI of a new $3.7M grant from NIH to assess clinical trials aimed at curing blood disease worldwide

Launched in September 2018 by the National Heart, Lung, and Blood Institute (NHLBI), the NIH Cure Sickle Cell Initiative aims to transform the lives of individuals living with SCD by moving the most promising genetic therapies safely into clinical trials within five to 10 years.

The Cure Sickle Cell Initiative is actively engaging the sickle cell disease community and exploring the scientific questions needed to safely and effectively advance potential therapies. The Initiative will also consider ways to support clinical trial recruitment, novel-funding approaches, and the type of technical assistance most beneficial to the research community as it develops potential cures for SCD. 

For more details on this grant (Microfluidic BioChip Assays for Curative Therapies), refer to the following link.